Avirmax CMC

Avirmax CMC is a private gene therapy-focused CDMO in the San Francisco Bay Area that provides recombinant adeno-associated virus (rAAV/AAV) process development, GMP manufacturing, analytical testing, and characterization services. The company operates as a spin-off entity of Avirmax and focuses on supporting clients from transgene DNA sequence and vector design through final AAV drug product supply for clinical investigation. Its manufacturing offering is built around proprietary Bac-to-AAV and HEK293 production technologies, including VSaf rBV-Sf9 and Sf-RVF cell line-based platforms, with an emphasis on high-titer, low-empty-capsid AAV production. Avirmax CMC appears to be a services and platform company rather than a therapeutics developer, so public evidence does not indicate a proprietary clinical pipeline under the Avirmax CMC entity itself. The company also markets off-the-shelf AAV products and monoclonal AAV antibodies in addition to custom manufacturing and testing services.